MET gene copy number predicts worse overall survival in patients with non-small cell lung cancer (NSCLC); A systematic review and meta-analysis

PLoS ONE

Volumn 9, Issue 9, 2014, Pages

  Dimou, Anastasios ^a   Non, Lemuel ^a   Chae, Young Kwang ^b   Tester, William J ^a   Syrigos, Konstantinos N ^c  

^a ALBERT EINSTEIN MEDICAL CENTER   (United States)

^b NORTHWESTERN UNIVERSITY   (United States)

^c UNIVERSITY OF ATHENS   (Greece)

Author keywords

[No Author keywords available]

Indexed keywords

SCATTER FACTOR RECEPTOR; ANAPLASTIC LYMPHOMA KINASE; EPIDERMAL GROWTH FACTOR RECEPTOR; MET PROTEIN, HUMAN; ONCOPROTEIN; PROTEIN TYROSINE KINASE; ROS1 PROTEIN, HUMAN;

CANCER PROGNOSIS; COHORT ANALYSIS; FLUORESCENCE IN SITU HYBRIDIZATION; GENE AMPLIFICATION; GENE DOSAGE; GENE EXPRESSION; GENETIC ASSOCIATION; GENETIC HETEROGENEITY; HISTOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; MET GENE; NON SMALL CELL LUNG CANCER; ONCOGENE; OVERALL SURVIVAL; RETROSPECTIVE STUDY; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; REVIEW; SYSTEMATIC REVIEW (TOPIC); GENETICS; LUNG TUMOR; META ANALYSIS; MORTALITY; SURVIVAL; TREATMENT OUTCOME;

CARCINOMA, NON-SMALL-CELL LUNG; GENE DOSAGE; HUMANS; LUNG NEOPLASMS; PROTEIN-TYROSINE KINASES; PROTO-ONCOGENE PROTEINS; PROTO-ONCOGENE PROTEINS C-MET; RECEPTOR PROTEIN-TYROSINE KINASES; RECEPTOR, EPIDERMAL GROWTH FACTOR; RETROSPECTIVE STUDIES; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 84907212532     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0107677     Document Type: Review

References (34)

1. Jemal A, Bray F, Center MM, Ferlay J, Ward E, et al. (2011) Global cancer statistics. CA Cancer J Clin 61: 69-90. doi:10.3322/caac.20107.
2. Hirsch FR, Janne PA, Eberhardt WE, Cappuzzo F, Thatcher N, et al. (2013) Epidermal growth factor receptor inhibition in lung cancer: status 2012. J Thorac Oncol 8: 373-384. doi:10.1097/JTO.0b013e31827ed0ff.
3. Sasaki T, Janne PA (2011) New strategies for treatment of ALK-rearranged nonsmall cell lung cancers. Clin Cancer Res 17: 7213-7218. doi:10.1158/1078-0432.CCR-11-1404.
4. Langer CJ, Besse B, Gualberto A, Brambilla E, Soria JC (2010) The evolving role of histology in the management of advanced non-small-cell lung cancer. J Clin Oncol 28: 5311-5320. doi:10.1200/JCO.2010.28.8126.
5. Turke AB, Zejnullahu K, Wu YL, Song Y, Dias-Santagata D, et al. (2010) Preexistence and clonal selection of MET amplification in EGFR mutant NSCLC. Cancer Cell 17: 77-88. doi:10.1016/j.ccr.2009.11.022.
6. Engelman JA, Zejnullahu K, Mitsudomi T, Song Y, Hyland C, et al. (2007) MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling. Science 316: 1039-1043. doi:10.1126/science.1141478.
7. Graziani A, Gramaglia D, dalla Zonca P, Comoglio PM (1993) Hepatocyte growth factor/scatter factor stimulates the Ras-guanine nucleotide exchanger. J Biol Chem 268: 9165-9168. PMID: 8387483.
8. Matsumoto K, Nakamura T (2006) Hepatocyte growth factor and the Met system as a mediator of tumor-stromal interactions. Int J Cancer 119: 477-483. doi:10.1002/ijc.21808.
9. Zhang YW, Wang LM, Jove R, Vande Woude GF (2002) Requirement of Stat3 signaling for HGF/SF-Met mediated tumorigenesis. Oncogene 21: 217-226. doi:10.1038/sj/onc/1205004.
10. Boccaccio C, Ando M, Tamagnone L, Bardelli A, Michieli P, et al. (1998) Induction of epithelial tubules by growth factor HGF depends on the STAT pathway. Nature 391: 285-288. doi:10.1038/34657.
11. Sequist LV, von Pawel J, Garmey EG, Akerley WL, Brugger W, et al. (2011) Randomized phase II study of erlotinib plus tivantinib versus erlotinib plus placebo in previously treated non-small-cell lung cancer. J Clin Oncol 29: 3307-3315. doi:10.1200/JCO.2010.34.0570.
12. Spigel DR, Ervin TJ, Ramlau RA, Daniel DB, Goldschmidt JH Jr, et al. (2013) Randomized phase II trial of Onartuzumab in combination with erlotinib in patients with advanced non-small-cell lung cancer. J Clin Oncol 31: 4105-4114. doi:10.1200/JCO.2012.47.4189.
13. Steels E, Paesmans M, Berghmans T, Branle F, Lemaitre F, et al. (2001) Role of p53 as a prognostic factor for survival in lung cancer: a systematic review of the literature with a meta-analysis. Eur Respir J 18: 705-719. PMID: 11716177.
14. Okuda K, Sasaki H, Yukiue H, Yano M, Fujii Y (2008) Met gene copy number predicts the prognosis for completely resected non-small cell lung cancer. Cancer Sci 99: 2280-2285. doi:10.1111/j.1349-7006.2008.00916.x.
15. Jin Y, Sun PL, Kim H, Seo AN, Jheon S, et al. (2013) MET Gene Copy Number Gain is an Independent Poor Prognostic Marker in Korean Stage I Lung Adenocarcinomas. Ann Surg Oncol. doi:10.1245/s10434-013-3355-1.
16. Tanaka A, Sueoka-Aragane N, Nakamura T, Takeda Y, Mitsuoka M, et al. (2012) Co-existence of positive MET FISH status with EGFR mutations signifies poor prognosis in lung adenocarcinoma patients. Lung Cancer 75: 89-94. doi:10.1016/j.lungcan.2011.06.004.
17. Kanteti R, Yala S, Ferguson MK, Salgia R (2009) MET, HGF, EGFR, and PXN gene copy number in lung cancer using DNA extracts from FFPE archival samples and prognostic significance. J Environ Pathol Toxicol Oncol 28: 89-98. PMID: 19817696.
18. Park S, Choi YL, Sung CO, An J, Seo J, et al. (2012) High MET copy number and MET overexpression: poor outcome in non-small cell lung cancer patients. Histol Histopathol 27: 197-207. PMID: 22207554.
19. Sun W, Song L, Ai T, Zhang Y, Gao Y, et al. (2013) Prognostic value of MET, cyclin D1 and MET gene copy number in non-small cell lung cancer. J Biomed Res 27: 220-230. doi:10.7555/JBR.27.20130004.
20. Tsuta K, Kozu Y, Mimae T, Yoshida A, Kohno T, et al. (2012) c-MET/phospho-MET protein expression and MET gene copy number in non-small cell lung carcinomas. J Thorac Oncol 7: 331-339. doi:10.1097/JTO.0-b013e318241655f.
21. Cappuzzo F, Marchetti A, Skokan M, Rossi E, Gajapathy S, et al. (2009) Increased MET gene copy number negatively affects survival of surgically resected non-small-cell lung cancer patients. J Clin Oncol 27: 1667-1674. doi:10.1200/JCO.2008.19.1635.
22. Chen YT, Chang JW, Liu HP, Yu TF, Chiu YT, et al. (2011) Clinical implications of high MET gene dosage in non-small cell lung cancer patients without previous tyrosine kinase inhibitor treatment. J Thorac Oncol 6: 2027-2035. doi:10.1097/JTO.0b013e3182307e92.
23. Dziadziuszko R, Wynes MW, Singh S, Asuncion BR, Ranger-Moore J, et al. (2012) Correlation between MET gene copy number by silver in situ hybridization and protein expression by immunohistochemistry in non-small cell lung cancer. J Thorac Oncol 7: 340-347. doi:10.1097/JTO.0b013e318240-ca0d.
24. Go H, Jeon YK, Park HJ, Sung SW, Seo JW, et al. (2010) High MET gene copy number leads to shorter survival in patients with non-small cell lung cancer. J Thorac Oncol 5: 305-313. doi:10.1097/JTO.0b013e3181ce3d1d.
25. Tachibana K, Minami Y, Shiba-Ishii A, Kano J, Nakazato Y, et al. (2012) Abnormality of the hepatocyte growth factor/MET pathway in pulmonary adenocarcinogenesis. Lung Cancer 75: 181-188.
26. Song L, Turkson J, Karras JG, Jove R, Haura EB (2003) Activation of Stat3 by receptor tyrosine kinases and cytokines regulates survival in human non-small cell carcinoma cells. Oncogene 22: 4150-4165. doi:10.1016/j.lungcan.2011.07.008.
27. Franci C, Zhou J, Jiang Z, Modrusan Z, Good Z, et al. (2013) Biomarkers of residual disease, disseminated tumor cells, and metastases in the MMTV-PyMT breast cancer model. PLoS One 8: e58183. doi:10.1371/journal.pone.0058183.
28. Sterne JA, Sutton AJ, Ioannidis JP, Terrin N, Jones DR, et al. (2011) Recommendations for examining and interpreting funnel plot asymmetry in meta-analyses of randomised controlled trials. BMJ 343: d4002. doi:10.1136/bmj.d4002.
29. Hotta K, Matsuo K, Ueoka H, Kiura K, Tabata M, et al. (2004) Role of adjuvant chemotherapy in patients with resected non-small-cell lung cancer: reappraisal with a meta-analysis of randomized controlled trials. J Clin Oncol 22: 3860-3867. PMID: 15326194.
30. Krishnaswamy S, Kanteti R, Duke-Cohan JS, Loganathan S, Liu W, et al. (2009) Ethnic differences and functional analysis of MET mutations in lung cancer. Clin Cancer Res 15: 5714-5723. doi:10.1158/1078-0432.CCR-09-0070.
31. Scagliotti GV, Novello S, Schiller JH, Hirsh V, Sequist LV, et al. (2012) Rationale and design of MARQUEE: a phase III, randomized, double-blind study of tivantinib plus erlotinib versus placebo plus erlotinib in previously treated patients with locally advanced or metastatic, nonsquamous, non-smallcell lung cancer. Clin Lung Cancer 13: 391-395. doi:10.1016/j.cllc.2012.01.003.
32. Scagliotti G, Novello S, Ramlau R, Favaretto A, Barlesi F, et al. (2013) MARQUEE: A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Trial of Tivantinib (ARQ 197) Plus Erlotinib Versus Placebo Plus Erlotinib in Previously Treated Patients With Locally Advanced or Metastatic, Non-Squamous, Non-Small-Cell Lung Cancer (NSCLC); 2013; Amsterdam, Netherlands.
33. Spigel DR, Edelman MJ, Mok T, O'Byrne K, Paz-Ares L, et al. (2012) Treatment Rationale Study Design for the MetLung Trial: A Randomized, Double-Blind Phase III Study of Onartuzumab (MetMAb) in Combination With Erlotinib Versus Erlotinib Alone in Patients Who Have Received Standard Chemotherapy for Stage IIIB or IV Met-Positive Non-Small-Cell Lung Cancer. Clin Lung Cancer 13: 500-504. doi:10.1016/j.cllc.2012.05.009.
34. Camidge D, Ou S, Shapiro G, Otterson G, Villaruz L, et al. (2014) Efficacy and safety of crizotinib in patients with advanced c-MET-amplified non-small cell lung cancer (NSCLC). J Clin Oncol 32: 5s, 2014 (suppl; abstr 8001).